Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note published on Wednesday morning. The firm issued a hold rating on the stock.

EKSO has been the topic of several other research reports. HC Wainwright restated a buy rating and set a $10.00 price target on shares of Ekso Bionics in a report on Tuesday, July 30th. Lake Street Capital assumed coverage on Ekso Bionics in a research report on Monday, June 24th. They set a buy rating and a $2.50 price objective for the company.

Ekso Bionics Price Performance

EKSO stock opened at $1.01 on Wednesday. The company has a current ratio of 2.42, a quick ratio of 1.77 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $18.36 million, a PE ratio of -1.04 and a beta of 1.45. Ekso Bionics has a 12-month low of $0.65 and a 12-month high of $3.13. The business’s fifty day moving average price is $1.12 and its 200 day moving average price is $1.20.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The company had revenue of $4.95 million for the quarter, compared to analysts’ expectations of $5.34 million. During the same quarter last year, the company earned ($0.31) EPS. On average, sell-side analysts anticipate that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC lifted its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.